TickerFacts.

YD Bio Ltd (YDES): Cost of Revenue

Annual figures by period end, from SEC filings.

$429.4K
Year ended 2025-12-31
2023-12-31: $196.7K2024-12-31: $355.0K2025-12-31: $429.4K$429.4K
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$429.4K+21.0%2026-04-30, From 2025-01-01
2024-12-31$355.0K+80.5%2026-04-30, From 2024-01-01
2023-12-31$196.7Kn/a2026-04-30, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
YD Bio Ltd (YDES)2025-12-31$429.4K+21.0%
Sera Prognostics, Inc. (SERA)2025-12-31$164.0K+100.0%
Aclarion, Inc. (ACON)2025-12-31$68.9K-18.6%
BioNexus Gene Lab Corp (BGLC)2025-12-31$6.34M-22.9%
American Shared Hospital Services (AMS)2025-12-31$23.02M+20.2%
Exagen Inc. (XGN)2025-12-31$27.78M+23.3%
Personalis, Inc. (PSNL)2025-12-31$53.87M-6.8%
BillionToOne, Inc. (BLLN)2025-12-31$96.65M+34.9%
Fulgent Genetics, Inc. (FLGT)2025-12-31$191.80M+8.8%

Compare YDES, SERA, ACON, BGLC side by side · Screen every company in Services-Medical Laboratories ↗